|
1
|
Smits VA and Gillespie DA: DNA damage
control: Regulation and functions of checkpoint kinase 1. FEBS J.
282:3681–3692. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sanchez Y, Wong C, Thoma RS, Richman R, Wu
Z, Piwnica-Worms H and Elledge SJ: Conservation of the Chk1
checkpoint pathway in mammals: Linkage of DNA damage to Cdk
regulation through Cdc25. Science. 277:1497–1501. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Narayanaswamy PB, Tkachuk S, Haller H,
Dumler I and Kiyan Y: CHK1 and RAD51 activation after DNA damage is
regulated via urokinase receptor/TLR4 signaling. Cell Death Dis.
7:e23832016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McNeely S, Beckmann R and Bence Lin AK:
CHEK again: Revisiting the development of CHK1 inhibitors for
cancer therapy. Pharmacol Ther. 142:1–10. 2014. View Article : Google Scholar
|
|
5
|
Kuo C-Y, Zupkó I, Chang F-R, Hunyadi A, Wu
C-C, Weng T-S and Wang H-C: Dietary flavonoid derivatives enhance
chemotherapeutic effect by inhibiting the DNA damage response
pathway. Toxicol Appl Pharmacol. 311:99–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Massey AJ, Stokes S, Browne H, Foloppe N,
Fiumana A, Scrace S, Fallowfield M, Bedford S, Webb P, Baker L, et
al: Identification of novel, in vivo active Chk1 inhibitors
utilizing structure guided drug design. Oncotarget. 6:35797–35812.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Origanti S, Cai SR, Munir AZ, White LS and
Piwnica-Worms H: Synthetic lethality of Chk1 inhibition combined
with p53 and/or p21 loss during a DNA damage response in normal and
tumor cells. Oncogene. 32:577–588. 2013. View Article : Google Scholar
|
|
8
|
Gokulnath M, Swetha R, Thejaswini G,
Shilpa P and Selvamurugan N: Transforming growth factor-β1
regulation of ATF-3, c-Jun and JunB proteins for activation of
matrix metal-loproteinase-13 gene in human breast cancer cells. Int
J Biol Macromol. 94:370–377. 2017. View Article : Google Scholar
|
|
9
|
Zabludoff SD, Deng C, Grondine MR, Sheehy
AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, et
al: AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint
abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther.
7:2955–2966. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Azorsa DO, Gonzales IM, Basu GD, Choudhary
A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff
DD, et al: Synthetic lethal RNAi screening identifies sensitizing
targets for gemcitabine therapy in pancreatic cancer. J Transl Med.
7:432009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu S, Liu Y, Minami K, Chen A, Wan Q, Yin
Y, Gan L, Xu A, Matsuura N, Koizumi M, et al: Inhibiting checkpoint
kinase 1 protects bone from bone resorption by mammary tumor in a
mouse model. Oncotarget. 9:9364–9378. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zannini L, Delia D and Buscemi G: CHK2
kinase in the DNA damage response and beyond. J Mol Cell Biol.
6:442–457. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu X, Webster SR and Chen J:
Characterization of tumor-associated Chk2 mutations. J Biol Chem.
276:2971–2974. 2001. View Article : Google Scholar
|
|
14
|
Hamamura K, Minami K, Tanjung N, Wan Q,
Koizumi M, Matsuura N, Na S and Yokota H: Attenuation of malignant
phenotypes of breast cancer cells through eIF2α-mediated
downregulation of Rac1 signaling. Int J Oncol. 44:1980–1988. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hamamura K, Tanjung N and Yokota H:
Suppression of osteoclastogenesis through phosphorylation of
eukaryotic translation initiation factor 2 alpha. J Bone Miner
Metab. 31:618–628. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Z, Lv Y, Zhao N, Guan G and Wang J:
Protein kinase R-like ER kinase and its role in endoplasmic
reticulum stress-decided cell fate. Cell Death Dis. 6:e18222015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Raschke WC, Baird S, Ralph P and Nakoinz
I: Functional macrophage cell lines transformed by Abelson leukemia
virus. Cell. 15:261–267. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang D, Christensen K, Chawla K, Xiao G,
Krebsbach PH and Franceschi RT: Isolation and characterization of
MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo
differentiation/mineralization potential. J Bone Miner Res.
14:893–903. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kato Y, Boskey A, Spevak L, Dallas M, Hori
M and Bonewald LF: Establishment of an osteoid preosteocyte-like
cell MLO-A5 that spontaneously mineralizes in culture. J Bone Miner
Res. 16:1622–1633. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lelekakis M, Moseley JM, Martin TJ, Hards
D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, et al:
A novel orthotopic model of breast cancer metastasis to bone. Clin
Exp Metastasis. 17:163–170. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen A, Wang L, Li B-Y, Sherman J, Ryu JE,
Hamamura K, Liu Y, Nakshatri H and Yokota H: Reduction in migratory
phenotype in a metastasized breast cancer cell line via
down-regulation of S100A4 and GRM3. Sci Rep. 7:34592017. View Article : Google Scholar
|
|
22
|
Moldovan NI, Hibino N and Nakayama K:
Principles of the Kenzan method for robotic cell spheroid-based
three-dimensional bioprinting. Tissue Eng Part B Rev. 23:237–244.
2017. View Article : Google Scholar
|
|
23
|
Hirao A, Kong YY, Matsuoka S, Wakeham A,
Ruland J, Yoshida H, Liu D, Elledge SJ and Mak TW: DNA
damage-induced activation of p53 by the checkpoint kinase Chk2.
Science. 287:1824–1827. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang X, Kua H-Y, Hu Y, Guo K, Zeng Q, Wu
Q, Ng HH, Karsenty G, de Crombrugghe B, Yeh J, et al: p53 functions
as a negative regulator of osteoblastogenesis, osteoblast-dependent
osteoclastogenesis, and bone remodeling. J Cell Biol. 172:115–125.
2006. View Article : Google Scholar
|
|
25
|
Cailleau R, Young R, Olivé M and Reeves WJ
Jr: Breast tumor cell lines from pleural effusions. J Natl Cancer
Inst. 53:661–674. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Soule HD, Vazguez J, Long A, Albert S and
Brennan M: A human cell line from a pleural effusion derived from a
breast carcinoma. J Natl Cancer Inst. 51:1409–1416. 1973.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yokota H, Hamamura K, Chen A, Dodge TR,
Tanjung N, Abedinpoor A and Zhang P: Effects of salubrinal on
development of osteoclasts and osteoblasts from bone marrow-derived
cells. BMC Musculoskelet Disord. 14:1972013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
National Research Council (US) Committee:
Guide for the Care and Use of Laboratory Animals. 8th edition.
National Academies Press; Washington, DC: 2011
|
|
29
|
Ascione F, Vasaturo A, Caserta S,
D'Esposito V, Formisano P and Guido S: Comparison between
fibroblast wound healing and cell random migration assays in vitro.
Exp Cell Res. 347:123–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang J, Zhu L and Peng B: Effect of
BioAggregate on osteoclast differentiation and inflammatory bone
resorption in vivo. Int Endod J. 48:1077–1085. 2015. View Article : Google Scholar
|
|
31
|
Miyazaki T, Miyauchi S, Anada T, Imaizumi
H and Suzuki O: Evaluation of osteoclastic resorption activity
using calcium phosphate coating combined with labeled polyanion.
Anal Biochem. 410:7–12. 2011. View Article : Google Scholar
|
|
32
|
Hamamura K, Swarnkar G, Tanjung N, Cho E,
Li J, Na S and Yokota H: RhoA-mediated signaling in
mechanotransduction of osteoblasts. Connect Tissue Res. 53:398–406.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wei W, Clockaerts S,
Bastiaansen-Jenniskens YM, Gierman LM, Botter SM, Bierma-Zeinstra
SM, Weinans H, Verhaar JA, Kloppenburg M, Zuurmond AM, et al:
Statins and fibrates do not affect development of spontaneous
cartilage damage in STR/Ort mice. Osteoarthritis Cartilage.
22:293–301. 2014. View Article : Google Scholar
|
|
34
|
Dalby KN, Tekedereli I, Lopez-Berestein G
and Ozpolat B: Targeting the prodeath and prosurvival functions of
autophagy as novel therapeutic strategies in cancer. Autophagy.
6:322–329. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Clezardin P and Teti A: Bone metastasis:
Pathogenesis and therapeutic implications. Clin Exp Metastasis.
24:599–608. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bieging KT, Mello SS and Attardi LD:
Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev
Cancer. 14:359–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sausville E, Lorusso P, Carducci M, Carter
J, Quinn MF, Malburg L, Azad N, Cosgrove D, Knight R, Barker P, et
al: Phase I dose-escalation study of AZD7762, a checkpoint kinase
inhibitor, in combination with gemcitabine in US patients with
advanced solid tumors. Cancer Chemother Pharmacol. 73:539–549.
2014. View Article : Google Scholar : PubMed/NCBI
|
